Eva Maria Garcia-Martinez

Eva Maria Garcia-Martinez

Auto-generated profile, based on publicly available information

Eva Maria Garcia-Martinez

Servicio de Farmacia Hospitalaria, Gerencia de Atención Integrada de Albacete, Albacete, España

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in Biochemical Pharmacology
Verified
Journal Article
Closed access
EGEva Maria Garcia-Martinez
Eva Maria Garcia-Martinez
SSSara Sanz-Blasco
Sara Sanz-Blasco
AKAndonis Karachitos
Andonis Karachitos
MBManuel Bández-Ruiz
Manuel Bández-Ruiz
Francisco-Jose Fernandez-GomezFrancisco-Jose Fernandez-Gomez
Francisco-Jose Fernandez-Gomez
Joaquin JordanJoaquin Jordan
Joaquin Jordan

12 June 2014 in Dermatology
Verified
Journal Article
Closed access
PDF file
NPNatalia Palmou-Fontana
Natalia Palmou-Fontana
JGJuan Antonio Sánchez Gaviño
Juan Antonio Sánchez Gaviño
DMDennis McGonagle
Dennis McGonagle
EGEva García-Martinez
Eva García-Martinez
LMLuis Iñiguez de Onzoño Martín
Luis Iñiguez de Onzoño Martín
Tocilizumab (TCZ) is a humanized monoclonal antibody against the interleukin-6 (IL-6) receptor and has been approved for the treatment of rheumatoid arthritis (RA) patients who have had an inadequate response to previous biological therapies. Psoriasiform skin lesions, especially palmoplantar pustulosis lesions, are well described following anti-tumour necrosis factor therapy. We describe a 79-year-old woman with rheumatoid factor-positive, anti-citrullinated protein antibody-positive erosive RA, who developed a psoriasiform palmoplantar pustulosis reaction following treatment with TCZ therapy (IL-6 receptor). The rash showed histological features compatible with psoriasis and disappeared following discontinuation of TCZ.


1 March 2011 in Farmacia Hospitalaria
Verified
Journal Article
Open access
FHFrancisco Hernández-Fernández
Francisco Hernández-Fernández
JPJ.M. Pardal-Fernández
J.M. Pardal-Fernández
EGE. García-Martínez
E. García-Martínez
Tomás SeguraTomás Segura
Tomás Segura

1 December 2017 in Revista Española de Anestesiología y Reanimación
Verified
Journal Article
Closed access
EDE. Domingo-Chiva
E. Domingo-Chiva
MDM. Díaz-Rangel
M. Díaz-Rangel
JMJ.á. Monsalve-Naharro
J.á. Monsalve-Naharro
PCP. Cuesta-Montero
P. Cuesta-Montero
JCJ.V. Catalá-Ripoll
J.V. Catalá-Ripoll
EGE.M. García-Martínez
E.M. García-Martínez

1 July 2017 in American Journal of Therapeutics
Verified
Journal Article
Closed access
PDF file
JRJosé Marco-Del Río
José Marco-Del Río
EDEsther Domingo-Chiva
Esther Domingo-Chiva
PCPablo Cuesta-Montero
Pablo Cuesta-Montero
AVAna Valladolid-Walsh
Ana Valladolid-Walsh
EGEva María García-Martínez
Eva María García-Martínez
We describe a recent case of Stevens-Johnson Syndrome. A 49-year-old man was admitted to the Intensive Care Unit of an Anaesthesia and Resuscitation Department because of a Fournier gangrene that derived in a sepsis, ventilator-associated pneumonia, and renal failure. He was under treatment with cefepime and suffered a generalized status epilepticus, so started treatment with phenytoin. The next day he developed a “maculous cutaneous eruption in trunk and lower limbs” compatible with a Stevens-Johnson Syndrome. Stevens-Johnson Syndrome is a very severe and potentially fatal multiorganic disease, especially when present in critically ill patients, with a strong drug-related etiology, especially with antiepileptic drugs.